12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology
Key Takeaways
- Diabetes is diagnosed by HbA1c of 48 mmol/mol or more, fasting glucose of 7.0 mmol/L or more, or a 2-hour OGTT value of 11.1 mmol/L or more, confirmed on a second sample if asymptomatic.
- HbA1c is unreliable in haemoglobinopathy, haemolysis, recent transfusion, iron deficiency, pregnancy and chronic kidney disease.
- MODY is autosomal dominant, presents before 25 years without ketosis, and HNF1A subtypes are exquisitely sulfonylurea-sensitive.
Diabetes mellitus represents a heterogeneous group of metabolic disorders characterized by persistent hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. For MRCP(UK) Part 1, candidates must master the diagnostic criteria, non-glycaemic confounders of HbA1c, immunogenetic distinctions between autoimmune and monogenic diabetes, guideline-directed pharmacotherapy under NICE NG28, and surveillance protocols for microvascular end-organ damage.
1. Diagnostic Thresholds & Biochemical Confounders
Diagnostic Criteria (WHO & NICE)
Diabetes mellitus is confirmed when venous plasma glucose or glycated haemoglobin meets validated thresholds:
- Fasting Plasma Glucose (FPG): $\ge 7.0\text{ mmol/L}$ (fasting defined as no caloric intake for at least 8 hours).
- 2-Hour Post-75g Oral Glucose Tolerance Test (OGTT): $\ge 11.1\text{ mmol/L}$.
- Random Plasma Glucose: $\ge 11.1\text{ mmol/L}$ in the presence of classic osmotic symptoms (polyuria, polydipsia, unexplained weight loss, lethargy).
- Glycated Haemoglobin (HbA1c): $\ge 48\text{ mmol/mol}$ ($6.5%$).
Diagnostic Verification Algorithm:
- Symptomatic Patient (polyuria, polydipsia, weight loss) + 1 abnormal result → Confirmed Diabetes
- Asymptomatic Patient + 1 abnormal result → Requires repeat test on a subsequent day (concordant abnormal result confirms diagnosis)
- Asymptomatic Patient + Discordant results → The test that exceeded the diagnostic threshold should be repeated
Intermediate Hyperglycaemia (Prediabetes)
- Impaired Fasting Glucose (IFG): Fasting plasma glucose $6.1\text{–}6.9\text{ mmol/L}$ (WHO) with normal 2-hour OGTT ($< 7.8\text{ mmol/L}$).
- Impaired Glucose Tolerance (IGT): Fasting plasma glucose $< 7.0\text{ mmol/L}$ and 2-hour OGTT $7.8\text{–}11.0\text{ mmol/L}$.
- Prediabetes HbA1c Range: $42\text{–}47\text{ mmol/mol}$ ($6.0\text{–}6.4%$).
HbA1c Pitfalls & Non-Glycaemic Confounders
HbA1c reflects average ambient glycaemia over the approximate 120-day lifespan of circulating erythrocytes. Any clinical pathology that alters erythrocyte survival, haemoglobin structure, or glycation kinetics renders HbA1c unreliable:
| Mechanism | Clinical Conditions | Effect on Measured HbA1c | Alternative Diagnostic Strategy |
|---|---|---|---|
| Shortened Red Cell Lifespan | Haemolytic anaemia, hereditary spherocytosis, splenomegaly, acute blood loss recovery, recent blood transfusion, haemoglobinopathies (HbSS, HbSC, thalassaemia major), erythropoietin therapy, haemodialysis | Falsely Low | Fasting plasma glucose, 2-hour OGTT, or serum fructosamine (reflects 2–3 weeks of glycaemia) |
| Prolonged Red Cell Lifespan | Iron deficiency anaemia (delayed red cell turnover), vitamin B12 or folate deficiency, asplenia / post-splenectomy, severe hyperbilirubinaemia | Falsely High | Venous plasma glucose criteria (FPG / OGTT) |
| Chemical / Assay Interference | Uraemia (carbamylated haemoglobin formation), severe chronic alcoholism, high-dose aspirin/vitamin C ingestion, homozygous haemoglobin variants (interfering with ion-exchange HPLC) | Falsely Altered (variable direction) | Enzymatic / affinity chromatography assays or serial plasma glucose profiles |
MRCP Exam Pearl: Diagnostic Situations Where HbA1c Must NOT Be Used:
- Suspected Type 1 diabetes (rapid onset).
- Pregnancy or gestational diabetes.
- Children and young people (<18 years).
- Symptoms lasting <2 months.
- Acute pancreatic damage or secondary diabetes (e.g., pancreatitis, pancreatectomy, steroid-induced).
- Patients on medication causing rapid glucose rise (e.g., systemic high-dose corticosteroids, atypical antipsychotics).
2. Pathophysiology, Genetics & Classification
Type 1 Diabetes Mellitus (T1DM)
- Immunopathogenesis: T-cell-mediated autoimmune destruction of insulin-secreting $\beta$-cells within pancreatic islets of Langerhans. Overt clinical presentation occurs once $> 80\text{–}90%$ of $\beta$-cell mass is irreversibly eradicated.
- Immunogenetics: Polygenic susceptibility strongly linked to human leukocyte antigen (HLA) class II genes on chromosome 6p21:
- High-Risk Alleles: HLA-DR3-DQ2 and HLA-DR4-DQ8; individuals who are heterozygous DR3/DR4 carry the highest relative risk (>20-fold).
- Protective Allele: HLA-DR2 (specifically DQB1*0602 confers dominant protection).
- Circulating Autoantibodies:
- Anti-GAD65 (Glutamic Acid Decarboxylase 65): Most sensitive and persistent autoantibody into adult life (~80% positivity at onset).
- Anti-IA-2 (Insulinoma-Associated Antigen 2): Marker of rapid $\beta$-cell destruction; common in children.
- Anti-ZnT8 (Zinc Transporter 8): Target antigen in secretory granules; detects additional 10–15% of antibody-negative cases.
- Anti-Insulin Autoantibodies (IAA): Commonest in young infants; ceases to be diagnostic once exogenous insulin is injected.
- C-Peptide Secretion: Cleaved from proinsulin in equimolar amounts to endogenous insulin. In long-standing T1DM, stimulated C-peptide is low or undetectable ($< 200\text{ pmol/L}$). A preserved C-peptide level ($> 600\text{ pmol/L}$) more than 3 years after diagnosis strongly suggests Type 2 or monogenic diabetes.
Type 2 Diabetes Mellitus (T2DM)
- Pathophysiology: Characterized by peripheral insulin resistance (skeletal muscle, liver, adipose tissue) combined with progressive pancreatic $\beta$-cell secretory failure. Unchecked hepatic gluconeogenesis causes elevated fasting glucose, while impaired muscle glucose uptake (GLUT4 translocation defect) drives postprandial hyperglycaemia.
- Genetics: Highly polygenic (>400 risk loci identified, including TCF7L2, KCNQ1, PPARG), demonstrating higher concordance in monozygotic twins (~70–90%) than Type 1 diabetes (~30–50%).
Monogenic Diabetes: Maturity-Onset Diabetes of the Young (MODY)
MODY accounts for 1–2% of all diabetes cases. It is inherited in an autosomal dominant manner, typically presents before age 25, is non-ketotic, and occurs in the absence of pancreatic islet autoantibodies:
MODY Key Subtypes:
- HNF1A-MODY (MODY3, ~70%): Transcription factor defect → Low renal glucose threshold (glycosuria) → Marked hypersensitivity to low-dose sulfonylureas
- GCK-MODY (MODY2, ~30%): Glucokinase sensor defect → Elevated set-point for insulin release → Stable mild fasting hyperglycaemia (5.5–8.0 mmol/L) → No microvascular complications → No pharmacological treatment needed
- HNF4A-MODY (MODY1, ~5%): Transcription factor defect → Neonatal macrosomia, transient neonatal hypoglycaemia → Responsive to sulfonylureas
- GCK-MODY in Pregnancy Exception: If the mother has GCK-MODY and the fetus inherits the mutation, the fetus senses maternal glucose as normal; no treatment is needed. If the fetus does not inherit the mutation, maternal hyperglycaemia triggers fetal hyperinsulinaemia and macrosomia; maternal insulin therapy is required.
Latent Autoimmune Diabetes in Adults (LADA)
- Often termed "Type 1.5 diabetes". Represents slowly progressive autoimmune destruction in adults aged >30–35 years.
- Frequently misdiagnosed as Type 2 diabetes due to adult onset, absence of initial ketoacidosis, and modest response to oral agents.
- Diagnostic hallmarks: Anti-GAD65 antibody positivity, absence of metabolic syndrome features, and progression to absolute insulin requirement within months to 5 years.
A 24-year-old primigravida woman at 14 weeks of gestation is evaluated following an incidental fasting plasma glucose of 6.2 mmol/L on routine antenatal screening. A repeat fasting glucose 1 week later is 6.1 mmol/L. Her HbA1c is 44 mmol/mol (6.2%). She is asymptomatic, with a BMI of 22 kg/m². A detailed family history reveals that her mother, maternal aunt, and maternal grandfather all have lifelong mild asymptomatic fasting hyperglycaemia (consistently 5.8–6.6 mmol/L) that never required pharmacological therapy. Genetic testing confirms a heterozygous inactivating mutation in the glucokinase gene (GCK-MODY / MODY2). Subsequent cell-free fetal DNA testing reveals that the fetus has NOT inherited the maternal GCK mutation. What is the most appropriate management of the mother's diabetes during the remainder of this pregnancy?